대한뉴팜

054670KOSDAQ

57.0 / 100

Reference Date: 2026-09-08

Financial Score28.5 / 40

News Sentiment12.5 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: PER is significantly undervalued vs. peers but Operating Profit is on a declining trend. Slightly down 2.1% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

DaeHan New Pharm operates in various sectors including specialty pharmaceuticals, non-essential pharmaceuticals (obesity & wellness injectables), and animal pharmaceuticals, focusing on chronic disease treatments and expanding into new areas such as dementia and Parkinson's. The company is diversifying its business through animal pharmaceuticals and biotech, leveraging stem cell-based anti-aging and cell therapies. Sales are structured as a multi-product, small-volume model, and the company manages foreign exchange risks through asset-liability matching strategies.

Number of Employees

393people

Average Salary

62.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

5.19Industry Average 15.008.0Point

Half of industry avg (excellent)

PBR

0.58Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE

11.50Industry Average 8.004.0Point

In line with industry avg

Debt Ratio

41.35Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

0.5 / 3

Avg ▼0.4% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼19.0% (2-year basis)

ROE Trend

2.5 / 4

Avg ROE 12.2% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (22%)

Current 5,640Won52-week high 7,51052-week low 5,090

1-month return2.0Point

1m -2.08% (slight drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral[기재정정]사업보고서 (2025.12)2026-08-28
Neutral[기재정정]감사보고서제출2026-08-28
Neutral반기보고서 (2026.06)2026-08-14